Is iPLA2β a Novel Target for the Development of New Strategies to Alleviate Inflammatory Bowel Disease?

Dig Dis Sci. 2015 Dec;60(12):3504-6. doi: 10.1007/s10620-015-3874-7.

Authors

Toni Petan¹, Igor Križaj^{2

3}

Affiliations

¹ Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Jamova 39, 1000, Ljubljana, Slovenia. toni.petan@ijs.si.
² Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Jamova 39, 1000, Ljubljana, Slovenia. igor.krizaj@ijs.si.
³ Department of Chemistry and Biochemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, 1000, Ljubljana, Slovenia. igor.krizaj@ijs.si.

PMID: 26391270
DOI: 10.1007/s10620-015-3874-7

No abstract available

Publication types

Editorial
Comment

MeSH terms

Animals
Colitis / chemically induced*
Group VI Phospholipases A2 / metabolism*
Humans
Male

Substances

Group VI Phospholipases A2